Everest Organics Ltd. (BSE: 524790) is a Hyderabad, Telangana-based company in the Pharmaceuticals industry. With a market capitalisation of ₹241 Cr, it ranks #2,499 by market cap among the 6,197 Indian listed companies on FinBizNet, and #34 of 63 in Pharmaceuticals. At ₹255.40 (as of 16 Nov 2026), the share price is 52.4% below its 52-week high of ₹536.40 and 29.6% above its 52-week low of ₹197.00. The share price is down 36.6% over one year and down 17.0% over three months.
| Current Price | ₹255.40 |
|---|---|
| Market Cap | ₹241 Cr |
| BSE Code | 524790 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 44.8 |
| Return on Equity | 7.63% |
| Return on Assets | 3.76% |
| 52-Week Range | ₹197.00 – ₹536.40 |
| 1-Year Price Change | -36.6% |
| 3-Month Price Change | -17.0% |
| Beta (1Y) | 0.75 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | www.everestorganicsltd.com |
| Revenue | ₹48 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 2.3% |
| EPS (Basic) | ₹1.15 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Everest Organics Ltd. reported revenue of ₹48 Cr in Q1 FY27, down 10.0% from ₹54 Cr in Q1 FY26 and down 0.7% from ₹49 Cr in Q4 FY26. It posted a net profit of ₹1 Cr for the quarter, against a net profit of ₹1 Cr in Q1 FY26 (down 21.3%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹41 Cr (Q4 FY25) to ₹54 Cr (Q1 FY26). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹48 Cr | ₹1 Cr | 2.3% |
| Q4 FY26 | ₹49 Cr | ₹3 Cr | 5.4% |
| Q3 FY26 | ₹43 Cr | ₹0 Cr | 0.8% |
| Q2 FY26 | ₹51 Cr | ₹1 Cr | 2.3% |
| Q1 FY26 | ₹54 Cr | ₹1 Cr | 2.6% |
| Q4 FY25 | ₹41 Cr | ₹3 Cr | 7.1% |
| Q3 FY25 | ₹42 Cr | ₹1 Cr | 2.7% |
| Q2 FY25 | ₹44 Cr | ₹1 Cr | 1.7% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 50.22% of Everest Organics Ltd.'s shares as of Mar 2026, against 50.15% in Mar 2025 (+0.07 percentage points). Delivery averaged 83.9% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Everest Organics Limited engages in the manufacture and sale of active pharmaceutical ingredients and its intermediaries in India. It is also involved in the manufacturing of bulk drugs-related business. The company exports its products. Everest Organics Limited was incorporated in 1993 and is based in Hyderabad, India.
1. Active Pharmaceuticals Ingredients (API) and Their Intermediates-This segment manufactures and sells pharmaceutical products. It offers active pharmaceutical ingredients and intermediaries.
1. Active Pharmaceutical Ingredients (API) and Their Intermediaries-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Everest Organics Ltd. | ₹241 Cr | 44.8 | 7.63% | ₹48 Cr | -36.6% |
Listed by market capitalisation. Ratios are shown for context only.
Everest Organics Ltd. is trading at ₹255.40, with a market capitalisation of ₹241 Cr.
Everest Organics Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Everest Organics Ltd. has a P/E of 44.8 and a return on equity of 7.63%.
Everest Organics Ltd. is listed on the BSE under the scrip code 524790.
Everest Organics Ltd.'s share price is down 36.6% over one year and down 17.0% over three months. Its 52-week range is ₹197.00 to ₹536.40.
In Q1 FY27, Everest Organics Ltd. reported revenue of ₹48 Cr and net profit of ₹1 Cr, with basic EPS of ₹1.15 (standalone, parsed from the company's exchange filing).
Everest Organics Ltd. reported revenue of ₹48 Cr in Q1 FY27, down 10.0% from ₹54 Cr in Q1 FY26 and down 0.7% from ₹49 Cr in Q4 FY26.
Promoters held 50.22% of Everest Organics Ltd.'s shares as of Mar 2026, against 50.15% in Mar 2025 (+0.07 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.